skip to main content

EGFR-mutant metastatic NSCLC — SCE Respiratory MCQ

Instant feedback + full explanation. One question, done properly.

HardLung CancerEGFR-mutant metastatic NSCLCSCE Respiratory

A 70-year-old woman has metastatic EGFR exon 19 deletion lung adenocarcinoma and no brain metastases. She is performance status 1 and has not received systemic therapy. What is the most appropriate first-line treatment?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — EGFR tyrosine kinase inhibitor therapy

An activating EGFR mutation in metastatic adenocarcinoma should guide first-line treatment towards an EGFR tyrosine kinase inhibitor. Cytotoxic chemotherapy may be used later or when targeted therapy is not suitable. Prophylactic cranial irradiation is not routine for EGFR-mutant NSCLC.

Reference: NICE NG122; NICE technology appraisal guidance for EGFR-mutant NSCLC